MammaPrint (70 genes) is a gene expression profiling test (also referred to as a ‘genomic test’, ‘genomic assay’, or ‘gene expression profiling test’) that reveals the distinct underlying biology of an early-stage breast cancer tumor to determine its risk of recurrence. This FDA-cleared and CE-marked gene expression profiling test assesses a woman’s risk of distant metastasis and based on clinical evidence, provides critical answers that inform the future of woman’s treatment plans at the point of diagnosis.